Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
H. Lundbeck A/S maintains 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 4 distinct examiners and 3 distinct art units. The distribution across multiple art units suggests the portfolio spans several specialized sub-sectors within the broader life sciences field.
KIM, YUNSOO serves as the busiest examiner for the company, handling 3 pending office actions. This concentration means that a significant portion of the company's current pending actions are under the review of a single individual. Practitioners should note that the remaining actions are spread among other examiners, requiring a balanced approach to examiner-specific negotiation across the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| No statute on record | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.4% |
| NOLAN, JASON MICHAEL | 1 | 66.5% | -27.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18511241 | TREATMENT OF MEDICATION OVERUSE HEADACHE USING ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES | CHERNYSHEV, OLGA N | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18511241 | TREATMENT OF MEDICATION OVERUSE HEADACHE USING ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES | CHERNYSHEV, OLGA N | 1675 | Other | Final Rejection | — | Pending | Nov 16, 2023 |
| 18252611 | MAGL INHIBITORS | NOLAN, JASON MICHAEL | 1623 | Other | Final Rejection | — | Pending | May 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial